An earlier study reported that TBK1 could be a target for cancer adjuvant therapy 12, then we further investigated the effects TBK1 on the drug sensitivity of CRC cells by transfecting HCT116 and SW480 cells with NC-siRNA or TBK1-siRNA combined with 5-FU to explore whether TBK1 could be a potential drug target in CRC therapy. Here, TBK1 is linked to cancer.